| A163 |
U3-1565 Biosimilar(Anti-HBEGF Reference Antibody)
Featured
|
|
|
| A164 |
KHK2866 Biosimilar(Anti-HBEGF Reference Antibody)
Featured
|
|
|
| A165 |
Tuvirumab Biosimilar（Anti-HBsAg Reference Antibody）
Featured
|
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research.
|
.png)
|
| A166 |
LY2787106 Biosimilar(Anti-Hepcidin / HAMP Reference Antibody)
Featured
|
|
|
| A167 |
Ludwig-Maximilians U. anti_Hepsin Biosimilar(Anti-Hepcidin / HAMP Reference Antibody)
Featured
|
|
|
| A168 |
TAK-701 Biosimilar(Anti-HGF / SF Reference Antibody)
Featured
|
|
|
| A169 |
Rilotumumab Biosimilar(Anti-HGF / SF Reference Antibody)
Featured
|
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. |
.png)
|
| A170 |
Ficlatuzumab Biosimilar（Anti-HGF / SF Reference Antibody）
Featured
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion. |
.png)
|
| A171 |
Genentech patent anti-HGFA Biosimilar（Anti-HGFA Reference Antibody）
Featured
|
|
|
| A172 |
Amivantamab Biosimilar（Anti-HGFR / c-Met Reference Antibody）
Featured
|
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells. |
.png)
|
| A173 |
Onartuzumab Biosimilar（Anti-HGFR / c-Met Reference Antibody）
Featured
|
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. |
.png)
|
| A174 |
Emibetuzumab Biosimilar（Anti-HGFR / c-Met Reference Antibody）
Featured
|
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer. |
.png)
|
| A175 |
Telisotuzumab Biosimilar（Anti-HGFR / c-Met Reference Antibody）
Featured
|
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity. |
.png)
|
| A176 |
SAIT301 Biosimilar（Anti-HGFR / c-Met Reference Antibody）
Featured
|
|
|
| A177 |
Korea RIBB patent anti-cMet Biosimilar（Anti-HGFR / c-Met Reference Antibody）
Featured
|
|
|
| A178 |
Metheresis patent anti-Met Biosimilar（Anti-HGFR / c-Met Reference Antibody）
Featured
|
|
|
| A179 |
Derlotuximab Biosimilar（Anti-Histone H1 Reference Antibody）
Featured
|
|
|
| A180 |
Immunomedics patent anti-Histone H2B Biosimilar（Anti-Histone H2B Reference Antibody）
Featured
|
|
|
| A181 |
Immunomedics patent anti-Histone H3 Biosimilar（Anti-Histone H3 Reference Antibody）
Featured
|
|
|
| A182 |
Immunomedics patent anti-Histone H4 Biosimilar（Anti-Histone H4 Reference Antibody）
Featured
|
|
|
| A183 |
IMMU-114 Biosimilar（Anti-HLA-DR Reference Antibody）
Featured
|
|
|
| A184 |
Galegenimab Biosimilar（Anti-HTRA1 Reference Antibody）
Featured
|
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research. |
.png)
|
| A185 |
Bersanlimab Biosimilar（Anti-ICAM1 / CD54 Reference Antibody）
Featured
|
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. |
.png)
|
| A186 |
Forerunner patent anti-ICAM-3 Biosimilar（Anti-ICAM3 / CD50 Reference Antibody）
Featured
|
|
|
| A187 |
Vopratelimab Biosimilar（Anti-ICOS / CD278 Reference Antibody）
Featured
|
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response. |
.png)
|
| A188 |
MEDI-570 Biosimilar（Anti-ICOS / CD278 Reference Antibody）
Featured
|
|
|
| A189 |
Alomfilimab Biosimilar（Anti-ICOS / CD278 Reference Antibody）
Featured
|
Alomfilimab(KY-1044; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response. |
.png)
|
| A190 |
Feladilimab Biosimilar（Anti-ICOS / CD278 Reference Antibody）
Featured
|
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer. |
.png)
|
| A191 |
LIMR patent anti-IDO2 Biosimilar(Anti-IDO2 Reference Antibody)
Featured
|
|
|
| A192 |
Sifalimumab Biosimilar(Anti-IFNa1 Reference Antibody)
Featured
|
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research. |
.png)
|
